Aclaris Therapeutics Statistics
Total Valuation
ACRS has a market cap or net worth of $136.43 million. The enterprise value is -$67.57 million.
Important Dates
The next estimated earnings date is Tuesday, May 20, 2025, after market close.
| Earnings Date | May 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRS has 108.28 million shares outstanding. The number of shares has increased by 10.73% in one year.
| Current Share Class | 108.28M |
| Shares Outstanding | 108.28M |
| Shares Change (YoY) | +10.73% |
| Shares Change (QoQ) | +33.52% |
| Owned by Insiders (%) | 2.67% |
| Owned by Institutions (%) | 45.19% |
| Float | 60.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.29 |
| Forward PS | 22.94 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.99 |
| Quick Ratio | 3.88 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -84.46% and return on invested capital (ROIC) is -20.59%.
| Return on Equity (ROE) | -84.46% |
| Return on Assets (ROA) | -15.72% |
| Return on Invested Capital (ROIC) | -20.59% |
| Return on Capital Employed (ROCE) | -27.83% |
| Revenue Per Employee | $292,500 |
| Profits Per Employee | -$2.06M |
| Employee Count | 64 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.73% in the last 52 weeks. The beta is 0.43, so ACRS's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -5.73% |
| 50-Day Moving Average | 1.49 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 41.13 |
| Average Volume (20 Days) | 854,176 |
Short Selling Information
The latest short interest is 4.07 million, so 3.76% of the outstanding shares have been sold short.
| Short Interest | 4.07M |
| Short Previous Month | 6.24M |
| Short % of Shares Out | 3.76% |
| Short % of Float | 6.68% |
| Short Ratio (days to cover) | 3.78 |
Income Statement
In the last 12 months, ACRS had revenue of $18.72 million and -$132.07 million in losses. Loss per share was -$1.71.
| Revenue | 18.72M |
| Gross Profit | -30.32M |
| Operating Income | -52.53M |
| Pretax Income | -59.05M |
| Net Income | -132.07M |
| EBITDA | -52.22M |
| EBIT | -52.53M |
| Loss Per Share | -$1.71 |
Full Income StatementBalance Sheet
The company has $113.59 million in cash and $2.60 million in debt, giving a net cash position of $201.30 million or $1.86 per share.
| Cash & Cash Equivalents | 113.59M |
| Total Debt | 2.60M |
| Net Cash | 201.30M |
| Net Cash Per Share | $1.86 |
| Equity (Book Value) | 155.55M |
| Book Value Per Share | 1.44 |
| Working Capital | 94.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.08 million and capital expenditures -$121,000, giving a free cash flow of -$20.20 million.
| Operating Cash Flow | -20.08M |
| Capital Expenditures | -121,000 |
| Free Cash Flow | -20.20M |
| FCF Per Share | -$0.19 |
Full Cash Flow StatementMargins
| Gross Margin | -161.99% |
| Operating Margin | -280.59% |
| Pretax Margin | -705.48% |
| Profit Margin | n/a |
| EBITDA Margin | -278.95% |
| EBIT Margin | -280.59% |
| FCF Margin | n/a |
Dividends & Yields
ACRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.73% |
| Shareholder Yield | -10.73% |
| Earnings Yield | -98.76% |
| FCF Yield | -15.10% |
Analyst Forecast
The average price target for ACRS is $11.67, which is 826.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.67 |
| Price Target Difference | 826.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 35.94% |
| EPS Growth Forecast (5Y) | -10.18% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ACRS has an Altman Z-Score of -4.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.79 |
| Piotroski F-Score | 2 |